- Report
- December 2024
- 120 Pages
Global
From €5679EUR$5,950USD£4,758GBP
- Report
- July 2024
- 175 Pages
Global
From €4772EUR$5,000USD£3,998GBP
- Report
- December 2024
- 200 Pages
Global
From €3579EUR$3,750USD£2,999GBP
- Report
- January 2025
- 182 Pages
Global
From €4295EUR$4,500USD£3,598GBP
- Report
- August 2024
- 140 Pages
Global
From €2862EUR$2,999USD£2,398GBP
- Report
- August 2022
- 214 Pages
Global
From €4580EUR$4,799USD£3,837GBP
- Report
- March 2025
Global
From €300EUR$337USD£260GBP
- Report
- May 2019
- 17 Pages
Global
From €596EUR$625USD£500GBP
€1193EUR$1,250USD£1,000GBP
- Report
- October 2024
- 94 Pages
Global
From €3500EUR$3,929USD£3,035GBP
- Report
- November 2021
- 747 Pages
Global
From €3818EUR$4,000USD£3,199GBP
Immunotoxins are a type of immune disorder drug that combines a toxin with an antibody or other targeting molecule to specifically target and destroy cells associated with an immune disorder. They are used to treat a variety of conditions, including cancer, autoimmune diseases, and infectious diseases. Immunotoxins are designed to target and destroy cells that are resistant to traditional treatments, such as chemotherapy and radiation. They are also used to reduce the side effects of other treatments.
Immunotoxins are typically administered intravenously or intratumorally, and can be used in combination with other treatments. They are generally well-tolerated and have few side effects. However, they can be expensive and may not be available in all countries.
Companies in the immunotoxins market include ImmunoGen, Inc., Seattle Genetics, Inc., and Merck KGaA. Show Less Read more